Kornimate/medical-research-clean huggingface dataset:
intravenous immunoglobulins in complex-regional pain syndrome

Conditions: Complex Regional Pain Syndrome Type 1

Summary: the purpose of this study is to determine whether intravenous immunoglobulins are effective in the treatment of complex-regional pain syndrome.

crps, a chronic pain syndrome associated with trophic disturbances is a frequent complication after limb trauma. more than one third of the crps will continue to chronic disease including loss of function in one limb. some reports implicate an autoimmune pathogenesis of crps. especially the finding of autoantibodies against peripheral neurons and successful treatment in single cases provide evidence for a possible successful treatment of crps with intravenous immunoglobulins (ivig). therefore ivig may be an important anti-inflammatory treatment to prevent severe chronification of crps. since ivig is mainly effective in b-cell-mediated autoimmune diseases, autoantibodies against autonomic neurons and the concentration of b-cell activating factors baff and april will be measured in the course of the study.

Eligibility criteria:
inclusion criteria: * crps 1 (according to the iasp criteria) between 6 weeks and 6 months after diagnosis * skin temperature of the affected side equal or higher than on non-affected side * no change of the analgetic or co-analgetic medication within the last 10 days exclusion criteria: * immunosuppressive or immunomodulatory treatment within the last three months * crps previously treated with sympathetic block, lidocaine patch, local dmso, spinal cord stimulation, intrathecal drug administration * known immune-mediated neuropathy (cidp, mmn, madsam) * selective iga-deficiency * severe heart disease * tumour disease in the last 5 years * allergy against gamunex 10% * chronic renal disease vaccination with live vaccine within the last three months * member of another clinical trial within the last 3 months

Keywords: complex regional pain syndrome sympathetic reflex dystrophy intravenous immunoglobulins autoimmune disease
reattachment of the spr versus the bone block procedure for recurrent peroneal tendon dislocation

Conditions: Recurrent Peroneal Tendon Dislocation

Summary: clinical outcomes between reattachment of the superior peroneal retinaculum (spr) and the bone block procedure were compared in this study to elucidate which procedure was safer and more effective.

from 2012 to 2016, 25 patients with recurrent peroneal tendon dislocation underwent the bone block procedure(group a), and another 22 patients underwent reattachment of the spr (group b). american orthopaedic foot and ankle society (aofas) ankle-hindfoot score, ankle activity score (aas), time to return to sports activity, rate of return to sports level, range of motion (rom) of the ankle, rate of recurrence, and overall patient satisfaction were collected to evaluate outcomes between the two groups.

Eligibility criteria:
inclusion criteria: * a traumatic recurrent peroneal tendon dislocation requiring surgery * a lack of response to at least 3 months of conservative treatment exclusion criteria: * the presence of an acute peroneal tendon dislocation * a concomitant anterior talofibular ligament rupture
evaluation of cross-linked collagen membrane with and without silk fibroin around immediate dental implants

Conditions: Immediate Implant

Summary: comparative evaluation of cross-linked collagen membrane with and without silk fibroin around immediate dental implants -randomized controlled trial.

periodontal disease is an inflammatory and infectious disease affecting the tooth supporting structures leading to tooth loss when left untreated.the detrimental effect of periodontitis results in soft tissue and hard tissue loss. bone defects has often resulted from tumor resection, congenital malformation, trauma, fractures, surgery, periodontitis or around implants in dentistry, as well as from diseases, such as osteoporosis or arthritis.these deficiencies have been overcome through various treatment modalities.it is a well-established fact that the cells from the periodontal ligament have the potential for regeneration of the tooth attachment apparatus. in addition, bone grafts and membranes have been used to regenerate the lost bone. among the membranes, autogenous connective tissue graft remains as gold standard. collagen is biocompatible natural polymer that has a good function to promote new tissue formation. in the proposed study, immediate implants with compromised bone support, cross-linked bovine collagen membrane will be used. it is a naturally occurring protein, having excellent biocompatibility, and hemostatic and chemotactic characteristics for gingival fibroblasts and periodontal ligaments. further, it is resistant to tension, controllable biodegradability, is non cytotoxic, low antigenicity, and excellent anti-inflammatory characteristics. it is naturally reabsorbed by microorganisms, easy to manipulate and has a molecular structure with little variance concerning the animal from which the collagen is extracted, leading to improved immunogenicity. bovine collagen is selected to enhance the biological function of silk fibroin, as composite membrane for enhancement of gingival thickness. thus, considering all these characteristics, silk fibroin is incorporated into collagen membrane for evaluation .as there is no literature assessing this composite membrane, the aim of this study compare evaluation of cross-linked collagen membrane with and without silk fibroin around immediate dental implants randomized controlled trial will be undertaken.

Eligibility criteria:
inclusion criteria * systemically healthy patients in the age group of 18 to 55years. * patients undergoing immediate implant placement with gingival thickness ≤ 1mm * stage ii /stage iii and grade b periodontitis patients. * radiographic assessment using radiovisiography (rvg) with grid. exclusion criteria: * patients having allergies with collagen and silk products. * medical conditions contraindicating surgical interventions. * known smokers and alcoholic. * acute infections at the site of extraction. ex abscess. * patients who have undergone radiotherapy or chemotherapy.

Keywords: silk fibroin with collagen membrane
study to evaluate efficacy, safety and tolerability of pennel capsule in the patients with chronic liver disease

Conditions: Chronic Liver Disease

Summary: the test agent in this study is a product of biphenylmethyl dicarboxylate (bdd) with garlic oil. the two components were confirmed to have complementary effects because of different operational mechanism in animal experiments, and were examined on humans in this study. both bdd and garlic oil are expected to show better protection and treatment on hepatotoxicity caused by toxic substances, and the purpose of this study is to confirm efficacy of and safety on human body of the agent and to determine its optimal dose.


Eligibility criteria:
inclusion criteria: * patients with chronic liver disease. * patients over 20, under 65 years of age. * patients with abnormal transaminase levels. exclusion criteria: * pregnant and lactating women. * patients who have any history of esophageal bleeding, hepatic encephalopathy, ascites. * diabetes, thyroid dysfunction, fatty liver, liver cancer patients. * toxic hepatitis, alcoholic hepatitis. * total bilirubin value more than 3.0 mg/dl. * albumin value less than 3.0 g/dl. * patients who participating in other study about drug.
sodium bicarbonate in preventing contrast induced nephropathy

Conditions: Contrast Induced Nephropathy

Summary: we plan to conduct an open-label, randomized, stratified, parallel-group study to compare normal saline infusion to sodium bicarbonate infusion.

we plan to conduct an open-label, randomized, stratified, parallel-group study to compare normal saline infusion to sodium bicarbonate infusion. 220 adult patients scheduled for routine cardiac catheterization will be enrolled. they will stratified according to the presence or absence of dm, or an estimated ger of less than 60 ml/hr before being block-randomized to the two groups. the incidence of cin will be determined based on the average of two measurements of creatinine level before and 48 hours after the procedure, and an increase of 25% or 0.5 mg/dl (44.2 umol/l) or more.

Eligibility criteria:
inclusion criteria: all adult patients (18 years and above) who are scheduled for cardiac catechization and have abnormal but stable renal function will be eligible for enrollment. abnormal renal function is defined as a creatinine level exceeding the normal range (more than 115 or 96 um/l in males and females, respectively, in kfsh\&rc laboratories) or egfr less than 60 ml/min exclusion criteria: patients who fall under any of the following categories will be excluded: * acute renal failure * cardiogenic shock * emergency cardiac catheterization * preexisting peritoneal or hemodialysis * pregnancy * recent exposure to contrast agent within the last 3 days * allergy to contrast or any of the above treatment * renal transplant, * patients who received dopamine, mannitol, theophyllin or other medications known to affect renal function within one week from cardiac cath * pulmonary edema / congestive heart failure * use of n-acetylcystein * patents on nsaids who can not stop using them for 48 hrs before and 48 hrs after procedure (except aspirin).

Keywords: contrast-induced-nephropathy, cardiac cath creatinine contrast nephropathy
shanghai atrial fibrillation registry

Conditions: Atrial Fibrillation (AF)

Summary: using the shanghai municipal health commission database and shanghai centers for disease control and prevention database, patients with af in shanghai are included to construct the shanghai af registry to investigate clinical characteristics, treatment, and prognosis.

1. to determine the most suitable risk stratification model for chinese af population regarding stroke and major cardiovascular events, i.e. cha2ds2-vasc, cha2ds2-vasc-60, or cha2ds2-va scores. 2. to compare the clinical prognosis of patients with af receiving the combined procedure of catheter ablation and left atrial appendage closure (laac), single catheter ablation, and single laac.

Eligibility criteria:
inclusion criteria: * with diagnosis of af: the diagnosis must be identified from the shanghai municipal health commission database and verified by 12-lead ecg or holter monitoring since 2015 * residents of shanghai * taking part in the government-issued health insurance, including the urban residents' basic medical insurance (urbmi), the urban-employ based medical insurance (uebmi) and the new rural cooperative medical scheme (nrcms). exclusion criteria: * non-residence of shanghai * without the government-issued health insurance * die at the day of index diagnosis of af

Keywords: atrial fibrillation left atrial appendage closure catheter ablation risk score chinese
the food intake, satiety and blood glucose after ingestion of potato chips produced from three potato cultivars

Conditions: Obesity; Overweight; Diabetes; Metabolic Syndrome

Summary: potato is one of the world's most popular foods and is widely accepted as a staple food. the objective of this study is to determine the effect of consuming potato chips from different cultivars on blood glucose, subjective appetite and food intake. it is hypothesized that the chips produced from various potato cultivars will differ in their effect on blood glucose, satiety and food intake.


Eligibility criteria:
inclusion criteria: * healthy men with a body mass index (kg/m2) of 20-24.9 exclusion criteria: * smocking, medication, breakfast skipping, restrained eating
optimization of frozen embryo transfers by studying progesterone on the day of transfer

Conditions: Infertility; IVF

Summary: the number of embryo transfers after freezing has increased over the last 10 years due to improvements in embryo freezing techniques and in particular the development of vitrification. this has also been made possible by changes in clinical protocols favouring freezing in patients at high risk of hyperstimulation and by different methods of endometrial preparation to receive embryos after rewarming. in fact, embryo transfer requires endometrial preparation to make implantation possible. there are various protocols for endometrial preparation. endometrial preparations in the natural cycle, with or without induction of ovulation by fsh, require more regular monitoring, and allow the development of a main follicle that will give a corpus luteum that will secrete progesterone in the luteal phase, which can be supported by the supply of exogenous progesterone. in contrast, endometrial preparations in hormone replacement therapy (hrt) cycles are done by administering estradiol orally or transdermally to stimulate endometrial growth while blocking the patient's gonadotropic axis, and administering progesterone in the luteal phase to differentiate the endometrium. this preparation has the advantage of being simpler to monitor and organize. there is currently no consensus on a type of preparation that would give better results, and although the literature seems to show that there would be more miscarriages in a substituted cycle, there does not seem to be any difference in the birth rate per cycle in the end, whatever the type of endometrial preparation. some teams have shown that in hrt, there appears to be more miscarriage when the progesterone level measured on the day of the frozen embryo transfer is lower, especially below a threshold of 9ng/ml. labarta showed eshre in july 2019 that modifying the endometrial preparation if the progesterone level is below 9ng/ml on the day of transfer by adding subcutaneous progesterone (progiron) resulted in a lower miscarriage rate, comparable to the usual miscarriage rates in spontaneous pregnancy. thus, if the miscarriage rate is higher in hrt than in the natural cycle, and if this is related to "luteal insufficiency" characterized by a lower circulating serum progesterone level, the hypothesis of this study in the investigator's population would be that the serum progesterone level on the day of the frozen embryo transfer would be lower in hrt than in the spontaneous cycle.


Eligibility criteria:
inclusion criteria: * patients who have benefited from a frozen embryo transfer during the inclusion period in the mpa centre of the chu caremeau nimes are included. * adult patient (≥18 years of age) and under 43 years of age. exclusion criteria: * patients who did not receive progesterone dosing on the day of transfer are excluded from the study. * patients who objected to the use of their data.
the detect(digital engagement & tracking for early control, & treatment) study

Conditions: Influenza; Virus

Summary: develop an app-based nationwide study of individuals who routinely use a smartwatch or other wearable activity tracker to determine if individualized tracking of changes in heart rate, activity and sleep can provide an early indication of influenza-like illnesses (ili) and possibly other viral infections.

this study will be configured in careevolution's mydatahelps platform. this app-based platform will allow people to: * provide informed consent electronically * donate robust smartwatch and activity tracker data, as well as self-reported data. * sensor-collected data, which will vary between devices, but what is shared will always be entirely up to the participant. investigators anticipate a minimum to include heart rate and activity, plus sleep duration when available. * this can include historical data collected by a sensor prior to the participants date of joining the study. * occasional survey-based participant-reported outcomes (pros). * participant-entered physiologic data such as oral temperature * passively share environmental data such as air quality and weather that will be captured from external sources based on participants' "home" zip code. optionally, if the participant consents to enable location/gps services on their smartphone, higher grain environmental data will be enabled. * optionally connect to and share their electronic health record (ehr) data in the event they have an event that requires interaction with a health care provider

Eligibility criteria:
inclusion criteria: * living in the u.s. * 18 years or older * android or iphone smartphone user * any connected wearable (apple watch, fitbit, garmin watch connected to apple health or google fit, amazfit) exclusion criteria:

Keywords: influenza viral infections influenza-like illnesses (ili) participant-reported outcomes (pro) electronic health record (ehr)
a phase ii trial of doxorubicin and genexol-pm in patients with advanced breast cancer

Conditions: Metastatic Breast Cancer

Summary: to evaluate efficacy and toxicity of doxorubicin/genexol-pm in metastatic breast cancer 1. primary purpose: response rate 2. secondary purpose: toxicity, progression-free survival, overall survival


Eligibility criteria:
inclusion criteria: * 18 years of age or older adult women * instrumentation measurable lesions with histologically confirmed advanced (recurrent or metastatic) breast cancer * ecog 0-2 * advanced breast cancer in the past, patients who did not receive chemotherapy * recurrence if adjuvant chemotherapy and adjuvant chemotherapy in the past for more than 6 months until the patient * life expectancy more than 3 months * agree in writing before the party to participate in a clinical trial to patients exclusion criteria: * immunohistochemical staining 3 + or fish positive anti-her 2 therapy patients * severe infections requiring antibiotic therapy * clinically significant heart disease * pregnant or lactating woman * uncontrolled symptoms in the central nervous system (cns) metastases * patients diagnosed with malignant tumors of other organs

Keywords: breast cancer doxorubicin genexol-pm paclitaxel
determination of the relative bioavailability of arq 197 tablet formulation with capsule c formulation as a reference in subjects with advanced solid tumors

Conditions: Solid Tumors

Summary: this is a phase 1, randomized, open label, 2 treatment, 2 period, 2-way crossover study, with an extension phase design in which the steady state pk of arq 197 will be investigated using the tablet administered in fed state (test treatment) and capsule administered at least 1 hour before or 2 hours after a meal (reference treatment) in subjects with advanced solid tumors.


Eligibility criteria:
inclusion criteria: * subjects must have a histologically or cytologically confirmed advanced solid tumor at screening. * male or female equal or greater than 18 years of age. * all female subjects of childbearing potential must each have a negative serum pregnancy test result before initiating study treatment. * an eastern cooperative oncology group (ecog) performance status equal or less than 2 * adequate bone marrow, liver, and renal function, defined as: * platelet count equal or greater than 75 x 10(9)/l * hemoglobin (hb) equal or greater than 9.0 g/dl * absolute neutrophil count (anc) equal or greater than 1.5 x 10(9)/l * total bilirubin equal or less than 1.5 x upper limit of normal (uln) * alanine aminotransferase (alt) and aspartate aminotransferase (ast) equal or less than 3 x uln (equal or less than 5 x uln for subjects with liver metastases) * serum creatinine equal or less than 1.5 x uln exclusion criteria: * history of cardiac disease: active coronary artery disease (cad), defined as myocardial infarction (mi), unstable angina, coronary bypass graft (cabg), or stenting within 6 months prior to study entry (an mi that occurred \> 6 months prior to study entry is permitted) * evidence of uncontrolled bradycardia or other cardiac arrhythmia defined as equal or greater than grade 2 according to nci ctcae, version 4.0, or uncontrolled hypertension * active, clinically serious infection(s) defined as equal or greater than grade 2 according to nci ctcae, version 4.0. * known metastatic brain or meningeal tumors, unless the subject is \> 3 months from definitive therapy and clinically stable (supportive therapy with steroids or anticonvulsant medications is allowed) with respect to the tumor at the time of first dose of study drug. * prior therapy with mesenchymal-epithelial transition factor (c-met) inhibitors, including arq 197.

Keywords: relative bioavailability arq 197
a pharmacokinetic study of ym178 in normal subjects and those with mild, moderate, and severe renal impairment

Conditions: Renal Impairment

Summary: the objective of this study is to assess and compare the pharmacokinetic properties of ym178 in normal subjects and those with mild, moderate and severe renal impairment.


Eligibility criteria:
inclusion criteria: * good health other than renal impairment * body mass index (bmi) between 18 and 40 kg/m2 exclusion criteria: * subject with renal impairment has not been on stable dose of concomitant medication for at least 2 weeks * subject has liver enzyme abnormalities

Keywords: mild, moderate, and severe renal impaired subjects normal renal function subjects glomerular filtration rate (gfr) modification of diet in renal disease (mdrd) formula ym178 pharmacokinetics
auscultate obese patients using electronic and traditional stethoscopes

Conditions: Chest Pathology

Summary: auscultating obese patients using the 3m littmann electronic model 3200 stethoscope is more effective in identifying referrable murmurs than using a traditional stethoscope.

study will enroll subjects who have greater than 30 bmi ratings. each subject will receive 4 auscultation examinations. two auscultations will be done by a cardiologist using both an acoustic traditional stethoscope and an electronic stethoscope. two additional auscultations will be done by a 3rd year medical resident also using both an acoustic traditional stethoscope and an electronic stethoscope. all determinations will be compared to echocardiography results.

Eligibility criteria:
inclusion criteria: * greater or equal than 18 years of age * referred for an echocardiogram * obese, as defined as having a bmi greater than 30 * volunteers to participate in study * agrees to provide copy of echocardiogram exam report exclusion criteria: -investigator believes subject should not be included or is unsuitable for inclusion

Keywords: chest pathology
a pragmatic trial integrating homelessness diversion services into an emergency department discharge system

Conditions: Homelessness

Summary: the purpose of this study is to determine whether a homelessness diversion program integrated into a hospital emergency department (ed) will lower ed use, to identify characteristics of individuals most likely to benefit from homelessness diversion and to discover opportunities to tailor homelessness diversion (hd) services to better meet the needs of diverse communities.


Eligibility criteria:
inclusion criteria: * english or spanish speaking * discharged from a harris health hospital ed (ben taub or lbj) * at imminent risk of homelessness * patients with medicaid, medicare or who are uninsured exclusion criteria: * having a conservator (legal guardian) * plans to move away from texas in 6 months